| Title |
Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial
|
|---|---|
| Published in |
Journal of Neuro-Oncology, March 2013
|
| DOI | 10.1007/s11060-013-1111-9 |
| Pubmed ID | |
| Authors |
Rajkumar Venkatramani, Lingyun Ji, Joseph Lasky, Kelley Haley, Alexander Judkins, Shengmei Zhou, Richard Sposto, Randal Olshefski, James Garvin, Tanya Tekautz, Gloria Kennedy, Shahrad Rod Rassekh, Theodore Moore, Sharon Gardner, Jeffrey Allen, Richard Shore, Christopher Moertel, Mark Atlas, Girish Dhall, Jonathan Finlay |
| Abstract |
This study investigates the outcome of children <10 years old with newly-diagnosed ependymoma treated on the prospective multinational "Head Start" III clinical trial. Between April 2004 and July 2009, 19 children with newly-diagnosed ependymoma were enrolled. All children were to receive five induction chemotherapy cycles followed by one consolidation cycle of myelo-ablative chemotherapy and autologous hematopoietic cell rescue. Children between 6 and 10 years of age or with residual tumor prior to consolidation were to receive irradiation thereafter. Median age of 19 children (8 female) was 20 months at diagnosis. Median follow up was 44 months. The primary site was infratentorial in 11 and supratentorial in 8 patients. Gross total resection was achieved in 10 patients. After induction chemotherapy, all three supratentorial ependymoma patients with residual disease achieved a complete response (CR), while only one of six infratentorial patients with residual disease achieved CR. Three infratentorial patients developed progressive disease during induction chemotherapy. All four infratentorial patients with residual disease who underwent autologous hematopoietic cell transplant, failed to achieve CR. Four patients received focal irradiation following chemotherapy. The 3-year event free survival (EFS) and overall survival (OS) for supratentorial ependymoma were 86 ± 13 % and 100 % respectively. The 3-year EFS and OS for infratentorial ependymoma were 27 ± 13 % and 73 ± 13 % respectively. The role of intensive induction and consolidation chemotherapy in deferring irradiation should be investigated further in children with supratentorial ependymoma with residual disease following surgery. This approach appears ineffective in children with infratentorial ependymoma in the absence of irradiation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 2% |
| Canada | 1 | 2% |
| Spain | 1 | 2% |
| Japan | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 59 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 17% |
| Other | 6 | 9% |
| Student > Master | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Student > Postgraduate | 5 | 8% |
| Other | 16 | 25% |
| Unknown | 14 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 48% |
| Agricultural and Biological Sciences | 4 | 6% |
| Neuroscience | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2013.
All research outputs
#15,267,294
of 22,703,044 outputs
Outputs from Journal of Neuro-Oncology
#1,940
of 2,958 outputs
Outputs of similar age
#123,562
of 197,433 outputs
Outputs of similar age from Journal of Neuro-Oncology
#15
of 32 outputs
Altmetric has tracked 22,703,044 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,958 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,433 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.